Overview
PT-141 (bremelanotide; synthetic amino acid sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) is a synthetic melanocortin receptor agonist derived from the alpha-melanocyte-stimulating hormone (α-MSH) sequence. It was developed from melanotan II (MTII) — a research compound that was found to produce unexpected sexual arousal as a side effect during tanning studies at the University of Arizona. PT-141 was specifically designed to retain the sexual arousal effect while minimizing the melanocyte stimulation (tanning) and nausea of its predecessor. Bremelanotide (Vyleesi®) received FDA approval in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women — the first FDA-approved drug acting centrally (not via hormonal or vascular mechanisms) to treat sexual dysfunction. Unlike sildenafil (Viagra) and similar PDE5 inhibitors that work peripherally on vascular smooth muscle, PT-141 acts in the central nervous system — specifically on melanocortin-4 receptors (MC4R) in the hypothalamus — to enhance sexual desire and arousal. This central mechanism makes it the only approved pharmacological option for women with HSDD and distinguishes it from all other approved sexual dysfunction medications.
Mechanism of Action
Melanocortin receptor agonism (MC3R, MC4R): PT-141 primarily acts on MC4R in the hypothalamus (paraventricular nucleus and medial preoptic area) and limbic regions to stimulate sexual motivation and arousal pathways. MC4R activation in these regions enhances dopaminergic reward signaling, increases norepinephrine release in sexual arousal circuits, and modulates oxytocin release — collectively producing increased sexual desire and physiological arousal responses.
Central vs peripheral mechanism: Unlike PDE5 inhibitors (which enhance peripheral vascular responses to existing arousal), PT-141 generates desire and arousal centrally — it can produce sexual arousal from a neutral baseline without requiring sexual stimulation as a prerequisite. This distinction is clinically important: PT-141 addresses the motivational/desire dimension; PDE5 inhibitors address the vascular/erectile dimension.
Erectogenic effect in men: MC4R activation in the paraventricular nucleus of the hypothalamus triggers spinal erection centers via descending serotonergic and dopaminergic pathways, producing penile erections in animal models and in human studies. This effect is independent of PDE5 inhibition.
Dual-sex efficacy: Unlike most sexual dysfunction drugs approved only for one sex, PT-141 has evidence for both enhanced sexual desire in women (Vyleesi approval) and improved erectile function in men — positioning it as potentially the only centrally acting drug with cross-sex sexual function indication.
No PDE5 inhibition: Unlike PDE5 inhibitors, PT-141 does not itself inhibit PDE5, and therefore does not carry the same nitrate interaction risk as sildenafil — but PT-141 has not been systematically studied alongside nitrates, and the transient BP elevation it causes means caution is still warranted in nitrate users. It does not produce the same hypotensive risk mechanism as PDE5 inhibitors, a meaningful clinical distinction for men with cardiac disease who use nitrates.
Evidence Base
FDA-approved for HSDD in premenopausal women: Phase III RCTs (RECONNECT studies; n=1,247 women): Vyleesi (1.75mg SQ) significantly increased satisfying sexual events per month (from 0.5 to 1.2 vs 0.7 with placebo; p<0.001) and significantly reduced HSDD distress scores. Effect size modest but statistically significant; FDA approval based on these trials.
Men with erectile dysfunction / HSDD: Phase II data in men support erectogenic and desire effects — PT-141 (2.5–10mg IN or SQ) significantly improved erectile function in men with organic ED not adequately responsive to sildenafil and improved sexual desire in men with hypoactive sexual desire. There is no current FDA indication in men; all male use remains off-label.
Post-SSRI sexual dysfunction: Off-label use reported in individuals with SSRI-induced sexual dysfunction — a population with limited alternatives given that PDE5 inhibitors address only the vascular component and not the desire component often affected by SSRIs.
Combination with PDE5 inhibitors: Some clinical evidence supports combining PT-141 with PDE5 inhibitors for synergistic effects on both desire and vascular components — addressing the full spectrum of sexual dysfunction rather than just one dimension.
Dosing & Timing
| Indication | Dose | Route | Timing | Notes |
|---|---|---|---|---|
| HSDD in women (FDA-approved) | 1.75 mg (Vyleesi) | SQ injection (self-administered) | 45 minutes before anticipated sexual activity | No more than once in 24 hours and no more than 8 doses per month; many clinicians prefer ≤1 dose/week for long-term use |
| Men (off-label) | 1–2 mg | SQ injection or intranasal | 30–60 min before activity | Physician supervised; lower starting dose |
| Post-SSRI sexual dysfunction | 1–2 mg | SQ injection | 45–60 min before activity | Off-label; discuss with prescribing physician |
Onset and duration: Effect begins within 30–45 minutes of SQ injection; duration 6–12 hours.
Nausea management: Nausea is the primary adverse effect — taking PT-141 on an empty stomach or using ondansetron 4mg orally 30 min before injection significantly reduces nausea incidence.
Forms & Bioavailability
Vyleesi® (bremelanotide): FDA-approved as a 1.75mg SQ autoinjector device (single-use, pre-filled); approved for premenopausal women with HSDD.
Compounded PT-141: Available from compounding pharmacies as powder for reconstitution (SQ injection) or intranasal spray. Compounded versions allow flexible dosing (lower doses to reduce side effects while titrating up) and intranasal administration.
Intranasal formulation: Earlier research used intranasal PT-141; produces slower absorption and lower peak levels than SQ; may reduce nausea incidence. Not FDA-approved via this route.
Safety & Side Effects
Very common (>10%): Nausea — most significant limitation; dose-dependent; typically mild-moderate; peaks 1–2 hours post-injection; resolves within 4 hours. Flushing, headache, and injection site reactions also common.
Transient blood pressure elevation: PT-141 can transiently increase systolic BP by 6–10 mmHg, with concurrent decrease in HR. These changes were small but consistent in trials. This effect is self-limiting (resolves within 12 hours), but patients with uncontrolled hypertension or established cardiovascular disease should be screened before use. Monitor BP before and after first use.
Hyperpigmentation: Transient darkening of face, gums, or breasts possible due to MC1R activation; reverses after stopping. More common with MTII (predecessor) than PT-141 at approved doses.
Contraindicated in: Uncontrolled hypertension, cardiovascular disease with hemodynamic instability, pregnancy (no safety data), prior hypersensitivity to melanocortin peptides.
NOT compatible with nitrates: While PT-141 does not inhibit PDE5, the combination with nitrates has not been formally studied and the transient BP elevation adds risk — caution in patients using nitrates.
Drug & Supplement Interactions
| Agent | Interaction | Management |
|---|---|---|
| PDE5 inhibitors (sildenafil, tadalafil) | Synergistic for sexual dysfunction (different mechanisms); potential additive hypotension | Start at lowest doses of both; monitor BP |
| Nitrates (nitroglycerin, isosorbide) | Caution: PT-141 causes transient BP elevation; nitrates lower BP | Avoid combination in unstable cardiac disease; consult cardiologist |
| Ondansetron | Reduces PT-141-associated nausea significantly | Standard pre-treatment for nausea management |
| Dopaminergic medications (L-DOPA) | Additive dopaminergic reward signaling | Generally safe; may potentiate desire effects |
| MAOIs | Theoretical CNS interaction via catecholamine pathways | Caution; discuss with physician |
Who Should Consider It
- Premenopausal women with HSDD (FDA-approved indication, Vyleesi)
- Men with erectile dysfunction inadequately responsive to PDE5 inhibitors, or with concurrent low sexual desire (off-label)
- Individuals with SSRI-induced sexual dysfunction affecting desire (not only erection/lubrication)
- Those seeking a sexual dysfunction medication that can be used without nitrate contraindication concerns (vs PDE5 inhibitors)
- Partners with desire mismatch seeking episodic desire augmentation
Requires prescription: Vyleesi requires FDA-registered prescriber in the US; compounded formulations require a prescription via compounding pharmacy.
Bottom Line
PT-141 / bremelanotide is the only FDA-approved medication for HSDD and the only centrally-acting sexual dysfunction drug available — a clinically meaningful distinction from PDE5 inhibitors that work purely on peripheral vascular response. Its approval was a landmark in women's sexual health, establishing for the first time that desire-phase dysfunction in women warranted pharmacological treatment beyond hormonal intervention. The off-label applications in men (erectile dysfunction with desire component, SSRI-induced sexual dysfunction) are supported by Phase II evidence and align with the mechanism. Nausea management (ondansetron pre-treatment or lower dosing via intranasal compounded formulation) is the most important practical consideration for maintaining tolerability and compliance.
Last reviewed: 2026.